Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

ns with several other parties regarding similar collaborations are ongoing. If successful, these collaborations could lead to these parties taking a licence to Silence delivery technologies.

Potential News Flow Events 2012-2014

In the near and medium term, the Directors believe there is the possibility of multiple potential news flow events from the existing product portfolio of programme deals, and opportunities within the RNAi technology platform, that could, dependent on success, act as value creation points for the business. The indicative dates are the Company's estimates, however no assurance can be given that the various events will be achieved by those dates, or indeed at all.

Internal Product Portfolio

Atu027 (treatment of solid tumours)

  • Completion of Phase I trial of Atu027 (July 2012)
  • Final Phase I results of Atu027 (third quarter of 2012)
  • Initiation of Phase Ib trial (end of 2012/early 2013)
  • Completion of Phase Ib trial (2014)

Atu111 (treatment of acute lung injury)

  • Completion of further proof-of-concept pre-clinical models (end 2012)

Partnered Product Portfolio

PF-'655 (diabetic macular oedema, glaucoma and age-related macular degeneration)

  • Completion of Phase IIb MATISSE study (2014)
  • Initiation of Phase IIa trial in glaucoma (trial start date not yet disclosed by Quark)

QPI-1002 (acute kidney injury 'AKI' and prevention of delayed graft function 'DGF')

  • Completion of Phase II trial in prevention of delayed graft function (second half of 2012)
  • Potential milestone payment upon Novartis' exercise of a license (2013)

Related Party Transaction

As part of the Fundraising, the Directors propose to issue 200,000,000 Subscription
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 RURO Inc. ... version 4.1, a versatile refinement to the smart ... solution, improves its advanced methodical management for transgenic ... ezColony 4.1. The network-based platform provides user access ... research. While continuing to emphasize streamlined tasks, such ...
(Date:5/17/2013)... 2013 Tooth decay is an epidemic in ... of the disease. The World Health Organization says that worldwide, ... adults have cavities. What are the long-term effects of this ... strong connection between the oral bacterial imbalance and serious systemic ... rampant, yet it is also 100% preventable? Answer: there has ...
(Date:5/16/2013)... PA (PRWEB) May 16, 2013 Oven ... pid temperature controllers and temperature sensors since 1964. ... widely used in industrial control system applications. ... the device includes a generic, control loop feedback system, ... are expertly used to adjust a systematic process, using ...
(Date:5/16/2013)... Cambridge Healthtech Institute will host its fifth annual ... Renaissance Waterfront Hotel in Boston, MA. The ten ... the current strategies and innovations for optimizing bioprocesses while ... the field will reveal how their work has resulted ... and efficiency. , “In this age of rapid innovation, ...
Breaking Biology Technology:RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3New PID Temperature Controllers Announced by Oven Industries Inc. 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2
... Call on Friday, March 13, 2009 at 8:30am ... Inc. (Nasdaq: KERX ), a biopharmaceutical ... of medically important, novel pharmaceutical products for the ... cancer (the "Company"), today announced its results for ...
... Burrill & Company Collaborating on Strategic Next Steps ... Developer Tower Investments, LLC ("Tower"), and San Francisco-based ... announced a formal partnership with aims of advancing ... and funding related to the "shovel-ready" BioBusiness Park ...
... , - ThromboGenics Reports Pre-Tax Profit ... ThromboGenics NV (Euronext Brussels: THR), a biotechnology company,focused on the ... difference to patient care in a number of important therapeutic,areas, ... for the,full year ending December 31, 2008. , ...
Cached Biology Technology:Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results 6Elk Run Developers Announce Partnership with Leading Life Sciences Firm 2Elk Run Developers Announce Partnership with Leading Life Sciences Firm 3Elk Run Developers Announce Partnership with Leading Life Sciences Firm 4ThromboGenics Announces Business Update and 2008 Full Year Results 2ThromboGenics Announces Business Update and 2008 Full Year Results 3ThromboGenics Announces Business Update and 2008 Full Year Results 4ThromboGenics Announces Business Update and 2008 Full Year Results 5ThromboGenics Announces Business Update and 2008 Full Year Results 6
(Date:5/16/2013)... scientists have shown a gene involved in neurodegenerative disease ... of the circadian clock. , In a study ... gene, called Ataxin-2, keeps the clock responsible for sleeping ... the rhythm of the fruit fly,s sleep-wake cycle is ... for the fly. , The discovery is particularly ...
(Date:5/16/2013)... players and athletes choose to wear the color red ... in Psychological Science , a journal of the ... to do with their testosterone levels. , The new ... University of Sunderland and colleagues, demonstrated that males who ... had higher testosterone levels than other males who chose ...
(Date:5/16/2013)... hematopoiesis at sites outside the bone marrow in ... (LMU) in Munich now show that a specific type ... blood cells. , Balanced hematopoiesis is essential for the ... takes place mainly in the liver and the spleen. ... and this tissue normally serves as the sole source ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 2High-testosterone competitors more likely to choose red 2Herpes infections: Natural killer cells activate hematopoiesis 2
... the Kimmel Cancer Center at Thomas Jefferson University in ... in regulating aging also blocks prostate cancer cell growth. ... Pestell, M.D., Ph.D., hope the newly found connection will ... and lead to new drugs against the disease. ...
... how an important protein converts chemical energy to mechanical ... to a new structural model by University of North ... model helps solve a scientific mystery: how the protein ... life. These functions include mitosis, or cell division into ...
... humble honey bee, researchers at the University of Illinois ... the molecular basis of social behavior in humans. , ... model system for social behavior," said Saurabh (pronounced SAW-rub) ... of the university's Institute for Genomic Biology. Using that ...
Cached Biology News:Jefferson scientists find aging gene also protects against prostate cancer development 2UNC scientists solve mystery of how largest cellular motor protein powers movement 2Honey bee genome holds clues to social behavior 2
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
Mouse monoclonal antibody raised against a partial recombinant FBXO11. NCBI Entrez Gene ID = FBXO11...
Mouse polyclonal antibody raised against a partial recombinant COASY. NCBI Entrez Gene ID = 80347...
MAb to Catenin beta, N-terminal (exon 2) Catenin, beta, N-terminal (exon 2)...
Biology Products: